7 hours Ago By Timothy Alexander
PHOENIXVILLE, PA — PleoPharma, Inc. has announced a significant intellectual property milestone with the issuance of its third U.S.
patent, aimed at addressing sleep disturbances linked to cannabis withdrawal syndrome (CWS). This FDA-recognized condition often impacts patients with cannabis use disorder (CUD), a growing focus in addiction medicine. The newly issued patent, No.
12,268,659, titled “Methods and Compositions for Treating Cannabis Use Disorder and Mitigating Cannabinoid Withdrawal,” provides proprietary claims for mitigating symptoms of CWS by improving sleep quality, depth, and duration. According to the patent, it also covers detailed dosing schedules and specific dose ranges associated with PP-01, the company’s leading investigational treatment. “We are pleased to have received our third issued patent,” said Ginger Constantine, MD, CEO of PleoPharma.
“Improving sleep quality, depth, and duration for patients suffering from CWS is an important aspect of PP-01 and a tremendous benefit in quality of life, especially for CUD patients.” PleoPharma noted that several pending patent applications are under review in both the U.S.
and international markets, reflecting its ongoing commitment to enhancing its intellectual property portfolio. This strategy underlines the company’s broader efforts to innovate treatments for underserved medical conditions like CUD. With this new patent in hand, PleoPharma looks to strengthen its leadership position in addressing the challenges faced by CUD patients and to further advance its research pipeline globally.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN ..
